China is a step closer to cracking down on unscrupulous data collection by app developers. The move follows in the footstep of a proposed data protection law that was released in October and is currently under review. The comprehensive data privacy law is set to be a "milestone" if passed and implemented, wrote the editorial of China Daily, the Chinese Communist Party's official mouthpiece.
Skanska has acquired about 2,787 square meters of land in Boston, Massachusetts. The seller is John Hancock Life Insurance Company. The land acquisition amounts to USD 177M, about SEK 1.5 billion.
ANNOUNCEMENT NO. 110 - 4 DECEMBER 2020In connection with the announced share buy-back program in Dampskibsselskabet NORDEN A/S, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcement no. 90.Kind regards,Dampskibsselskabet NORDEN A/SMartin BadstedCFOFor further information:Martin Badsted, CFO, tel.: +45 3315 0451Attachments * No. 110 Managers' transactions * Transactions by persons discharging managerial responsibilities and persons (30)
The happiest new year always starts with the sharing of food, well-wishes, laughter, and hearty conversations. Accompanied by the dazzling fireworks that grace us from the horizons, we are used to kickstarting the year with a resounding celebration, built up from not the obvious ornaments, but from the lights of our eyes and intimate conversations.
Ademi LLP is investigating possible securities fraud claims against Splunk (NASDAQ: SPLK) resulting from inaccurate statements Splunk made regarding its financial statements and prospects.
The Ad Hoc Bondholder Group (the "Group") of the Province of Cordoba (the "Province") firmly rejects the terms of the Province's amended Consent Solicitation announced by the Province on December 3, 2020. The Group is composed of institutional money managers holding in excess of 50% of the Province's international bonds subject to the Consent Solicitation.
Pomerantz LLP announces that a class action lawsuit has been filed against Turquoise Hill Resources Ltd. ("Turquoise Hill" or the "Company") (NYSE: TRQ), Rio Tinto plc, Rio Tinto Limited (together with Rio Tinto plc, "Rio Tinto"), Rio Tinto subsidiary Rio Tinto International Holdings Limited, and certain of their officers. The class action, filed in United States District Court for the Southern District of New York, and docketed under 20-cv-10198, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Turquoise Hill securities from July 17, 2018 to July 31, 2019, inclusive (the "Class Period"), and who were damaged thereby, subject to certain exclusions. Plaintiff seeks to recover compensable damages on behalf of Plaintiff and the Class caused by Defendants' violations of the federal securities laws under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder.
EMnify, a leading cloud communication platform provider for IoT, announced new turnkey integrations into Azure Event Hubs and Google Cloud Pub/Sub via its EMnify Data Streamer – a feature that enables real-time streaming of connectivity data into the cloud and self-developed software stacks. These integrations empower IoT support and business teams whose applications are deployed on Azure and Google Cloud with complete network transparency to faster triage and resolve issues.
LONDON, Dec. 4, 2020 Art&Co. ("Art&Co."), an initiative connecting the worlds of art, finance and support groups brings continued relief to COVID-19 victims. It is backed by PremFina ("PremFina" or the "Company"), the U.K.'s first venture capital backed alternative insurance premium finance company.
EchoStar Mobile today announced a partnership with Jersey Telecom (JT) to bring true, hybrid satellite/cellular capability to Internet of Things (IoT) and Mobility customers across Europe and the UK.
MRI Software has successfully applied to become a member of the Innovation Collaboration Group (ICG), demonstrating and deepening its commitment as a pioneer of open and connected technology platforms for the property sector.
Key Prominent Players Covered in the Teledermatology Market Research Report Are 3Gen, Ksyos, MetaOptima, 3Derm, VigNet Inc., Maple, MDLIVE Inc., CureSkin, Ping an Good Doctor, FirstDerm and other key market players.Pune, Dec. 04, 2020 (GLOBE NEWSWIRE) -- The global teledermatology market size is projected to reach USD 44.86 billion by the end of 2027. The presence of several large scale companies in this sector will have a huge impact on the growth of the overall market in the coming years. The market was worth USD 4.83 billion in 2019 and will exhibit a CAGR of 24.3% during the forecast period, 2020-2027. As of 2019, the market in North America was worth USD 2.04 billion and this value is projected to increase further in the coming years. KEY INDUSTRY DEVELOPMENTS: * May 2020 – DermTech, announced the launch of its DermTech Pigmented Lesion Assay, a telemedicine solution to enable remote use of its non-invasive adhesive patch test for melanoma detection. * April 2020 – Sakhiya Skin Clinic in India, announced the launch of cost free skin care treatment facilities via teledermatology platforms.Teledermatology is the combination of telehealth and dermatology and involves concepts such as AI and IoT. It is one of the most popular applications of e-health and telemedicine and serves the purpose of transferring medical information across longer as well as shorter distances through audio, video, and data communication. Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/teledermatology-market-103491 Teledermatology Manufacturers Among the Very Few Who Have Benefited from the Covid-19 PandemicThe recent coronavirus outbreak has created a sense of panic in several industries across the world. Accounting to the rapid spread of the disease, governments across the world are compelled to implement strict measures to curb the spread of the disease. As a result, people have been forced to stay indoors due to the strict lockdowns and social distancing practices implemented worldwide. Although the pandemic has had a daunting effect on several industries, that certainly hasn’t been the case for teledermatology companies. The surge in use of concepts such as telehealth and telemedicine has boded well for the growth of the overall teledermatology market in the past few months. Click here to get the short-term and long-term impact of COVID-19 on this Market.Please visit: https://www.fortunebusinessinsights.com/teledermatology-market-103491 Increasing Number of Product Launches Will Emerge in Favor of Market GrowthThe report encompasses several factors that have contributed to the growth of the overall market in recent years. Among all factors, the increasing investments in product R&D and the increasing number of product launches have made the highest impact on the growth of the market in recent years. The rising investments will also open up a flexible application scope, therefore creating a broader growth spectrum for the companies operating at a global as well as regional level. In April 2020, Sakhiya Skin Clinic announced the launch of free skin care treatment facilities across India. Quick Buy - Teledermatology Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/103491 North America to Emerge Dominant; Presence of Several Large Scale Companies to Aid GrowthThe report analyses the ongoing market trends across five major regions, including North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Among all regions, the market in North America is projected to emerge dominant in the coming years. The presence of several large scale companies in several countries across this region will emerge in favor of the regional market. The coronavirus outbreak will have a significant impact on the growth of the regional market in the coming years, particularly due to the rising demand for telemedicine tools in the past few months. It is likely that the increasing awareness regarding the use of online platforms even after the pandemic will encourage manufacturers in this region and this will subsequently influence the growth of the market in the foreseeable future. As of 2019, the market in North America was worth USD 2.04 billion and this value is projected to increase further in the coming years. Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/teledermatology-market-103491 List of companies profiled in the Teledermatology Market report: * 3Gen * Ksyos * MetaOptima * 3Derm * VigNet Inc. * Maple * MDLIVE Inc. * CureSkin * Ping an Good Doctor * FirstDerm * Other Players Global Teledermatology Market Segmentations:By Type• Products • Serviceso Teleconsultationo Telemonitoringo Tele-educationo Others By Modality• Store-and-forward (Asynchronous)• Real-time (Synchronous)• OthersBy End User• Healthcare Facilities• Home Care By Geography• North America (U.S. and Canada)• Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)• Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia- Pacific)• Rest of the World (RoW) Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/teledermatology-market-103491 SECONDARY DATA SOURCES THAT WE REFER TO: * Annual reports, investor presentation, SEC filings, and press releases of companies operating in the market * Studies published by relevant associations MedTech Europe; American College of Radiology; Cancer Council Australia; Japan Hospital Association, etc.), government sources (Centers for Disease Control & Prevention, Ministry of Health, Labour & Welfare, Japan; National Health Service, England, etc.), international organizations (World Health Organization, The Organization for Economic Co-operation and Development, Eurostat, etc.), and articles published by Research Gate, NCBI, etc. * Website, reports, and press releases of end user facilities – Hospitals, Ambulatory Surgery Centres, Clinics * Industry journals and paid databasesSECONDARY RESEARCH IS CONDUCTED TO DERIVE THE FOLLOWING INFORMATION: * Details such as revenues, market share, strategies, growth rate, product & their pricing by region/country for all major companies * Details in relation to prevalence, incidence, patient numbers, distribution of patients, average price of treatment, etc. * Number of end user facilities by region/country and average annual spending or procurement of devices by type of end user facility * Number of procedures and average price of procedures * Replacement rate and pricing of capital equipment * Market dynamics in relation to the market under focus – Drivers, restraints, trends, and opportunities * Market & technological trends, new product developments, product pipeline. Have a Look at Related Reports:Biomaterials Market Share and Industry Analysis, By Material (Metallic, Ceramic, Polymers, and Natural), By Application (Cardiovascular, Dental, Orthopedic, Plastic Surgery, Urology, Gastroenterology, and Others), and Regional Forecast, 2020-2027Skin Cancer Treatment Market Share & Industry Analysis, By Disease Indication (Melanoma and Non-Melanoma), By Therapy (Immunotherapy, Targeted Therapy, Chemotherapy, and Radiation Therapy), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Others), and Regional Forecast, 2020-2027Cardiac Biomarkers Market Share & Industry Analysis, By Indication (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, and Others), By Biomarker (Troponin, Creatine kinase-MB (CK-MB), B-type Natriuretic Peptide (BNP), Myoglobin, and Others), By End User (Hospitals, and Specialty Clinics), and Regional Forecast, 2020-2027Asthma Treatment Market Share & Industry Analysis, By Treatment (Long-Term Control Medications, and Quick-Relief Medications), By Route of Administration (Injectable, Oral, and Inhaled), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, and Online Pharmacies), and Regional Forecast, 2020-2027Legionella Testing Market Share & Industry Analysis, By Type (Culture Media, Urine Antigen Testing (UAT), Polymerase Chain Reaction (PCR), Serology, and Direct Fluorescent Antibody (DFA) test; By End User (Hospitals & Clinics, Diagnostic Centers, and Others) and Regional Forecast, 2020-2027 About Us:Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges. Contact Us:Fortune Business Insights™ Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India.Phone: US :+1 424 253 0390 UK : +44 2071 939123 APAC : +91 744 740 1245 Email: email@example.com Fortune Business Insights™ LinkedIn | Twitter | Blogs Press Release: https://www.fortunebusinessinsights.com/press-release/global-teledermatology-market-10187
Key Prominent Players Covered in the Telehealth Market Research Report Are American Well, MDLIVE Inc., Teladoc Health Inc., Doctor on Demand Inc., Dictum Health Inc., Grand Rounds Inc., OpenTeleHealth and other key market players.Pune, Dec. 04, 2020 (GLOBE NEWSWIRE) -- The report mentions that global telehealth market size was USD 61.40 billion in 2019 and is projected to reach USD 559.52 billion by 2027, exhibiting a CAGR of 25.2% during the forecast period. The global telehealth market is expected to grow astonishingly in the near future on account of the rising preference for e-visits. They provide easy access to the required doctors, lower outpatient department waiting times, and are cost-effective. North America procured USD 26.14 billion in terms of revenue. This growth is attributable to the presence of favorable health reimbursement policies, as well as several reputed companies in the region.KEY INDUSTRY DEVELOPMENTS: * March 2020 – The Ministry of Health and Family Welfare (MoHFW), in collaboration with the Board of Governors (BoG) Medical Council of India (MCI) and NITI Aayog issued guidelines for telemedicine practice in India. * January 2020 - Teladoc Health acquired InTouch Health which will provide the company with a network of more than 450 hospitals. * June 2019 – Zava, a telemedicine service provider, announced a USD 32 million series A investment for the expansion in Europe from the equity firm, HPE Growth. * April 2019 – InTouch Health announced the launch of Solo, an end-to-end fully integrated virtual care platform, which is suitable for any user type in any healthcare setting. * January 2019 – UnitedHealth Group announced the acquisition of Vivify Health, Inc., a remote patient monitoring company. Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/telehealth-market-101065 Rising Need to Maintain Social Distancing amidst COVID-19 will Favor Growth The outbreak of the COVID-19 pandemic has reduced the demand for medical devices owing to the rising burden on healthcare professionals and hospitals, as well as reduced hospital visits. Besides, several cases of elective surgery have been postponed. This has opened doors to new opportunities for these platforms and software solutions. Hence, the demand for virtual consultations is anticipated to surge on account of the current scenario. Telehealth is considered to be a very powerful weapon to battle the coronavirus pandemic. To avoid virus transmission while traveling to hospitals and clinics, people are rapidly inclining towards these digital platforms. Teladoc Health Inc., for instance, stated that as compared to the fourth quarter of 2019, the overall number of virtual consultations surged up to 60% and reached 2 million from January 2020 to March 2020. This proves that people are actively adopting remote monitoring and telehealth services worldwide to keep up with social distancing between the doctors and the patients. To get to know more about the short-term and long-term impacts of the COVID-19 pandemic, please visit: https://www.fortunebusinessinsights.com/industry-reports/telehealth-market-101065 Services Segment to Lead Backed by Rising Number of Virtual Consultations In terms of type, the market is bifurcated into services and products. Out of these, the services segment is set to dominate by generating the highest telehealth market share in the near future. This growth is attributable to the introduction of reimbursement policies for teleconsultations, rising fundings by various start-up companies, and increasing number of virtual consultations. The products segment is expected to grow steadily because of the high demand for numerous telecommunication devices, such as tablets. High Rural Population to Augment Growth in Asia Pacific Based on geography, in 2019, North America procured USD 26.14 billion in terms of revenue. This growth is attributable to the presence of favorable health reimbursement policies, as well as several reputed companies in the region. Apart from that, the region is adopting the latest technologies in the field of telehealth at a fast pace. Asia Pacific, on the other hand, is anticipated to grow remarkably in the near future on account of high rural population, technological advancements in digital imaging, and enhancements in healthcare scenario. Quick Buy - Telehealth Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/101065 List of Key Players in Telehealth Market: * American Well (Boston, U.S.) * MDLIVE Inc. (Sunrise, U.S) * Teladoc Health Inc. (Purchase, U.S.) * Doctor on Demand Inc. (San Francisco, U.S.) * Dictum Health Inc. (Oakland, U.S.) * Grand Rounds Inc. (San Francisco, U.S.) * OpenTeleHealth (Balticagade, Denmark) * Other Players Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/telehealth-market-101065 Global Telehealth Market Segmentation:By Type• Products• ServicesBy Application• Telemedicine• Patient Monitoring• Continuous Medical Education• OthersBy Modality• Store-and-forward (Asynchronous)• Real-time (Synchronous)• Remote Patient MonitoringBy End User• Healthcare Facilities• Homecare• OtherBy Geography• North America (the U.S. and Canada)• Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)• Asia-Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia- Pacific)• Latin America (Brazil, Mexico, and Rest of Latin America)• Middle East & Africa (GCC, South Africa, and Rest of Middle East & Africa) Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/telehealth-market-101065 SECONDARY DATA SOURCES THAT WE REFER TO: * Annual reports, investor presentation, SEC filings, and press releases of companies operating in the market * Studies published by relevant associations MedTech Europe; American College of Radiology; Cancer Council Australia; Japan Hospital Association, etc.), government sources (Centers for Disease Control & Prevention, Ministry of Health, Labour & Welfare, Japan; National Health Service, England, etc.), international organizations (World Health Organization, The Organization for Economic Co-operation and Development, Eurostat, etc.), and articles published by Research Gate, NCBI, etc. * Website, reports, and press releases of end user facilities – Hospitals, Ambulatory Surgery Centres, Clinics * Industry journals and paid databasesSECONDARY RESEARCH IS CONDUCTED TO DERIVE THE FOLLOWING INFORMATION: * Details such as revenues, market share, strategies, growth rate, product & their pricing by region/country for all major companies * Details in relation to prevalence, incidence, patient numbers, distribution of patients, average price of treatment, etc. * Number of end user facilities by region/country and average annual spending or procurement of devices by type of end user facility * Number of procedures and average price of procedures * Replacement rate and pricing of capital equipment * Market dynamics in relation to the market under focus – Drivers, restraints, trends, and opportunities * Market & technological trends, new product developments, product pipeline. Have a Look at Related Reports:Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market Share & Industry Analysis, By Disease Indication (Arthritis, Migraine, Ophthalmic Diseases, and Others), By Route of Administration (Oral, and Parenteral), By Distribution Channel (Hospital Pharmacy Retail Pharmacy, and Online Pharmacy), and Regional Forecast, 2020-2027Anti-Fungal Drugs Market Share & Industry Analysis, By Drug Type (Echinocandins, Azoles, Polyenes, and Allylamines), By Indication (Dermatophytosis, Aspergillosis, Candidiasis, and Others), By Route of Administration (Oral, Topical, and Parenteral), By Distribution Channel (Hospital Pharmacies, Retails Pharmacies & Drug Stores, and Others), and Regional Forecast, 2020-2027Anti-Inflammatory Drugs Market Share & Industry Analysis, By Drug Class (Anti-inflammatory Biologics, Non-steroidal Anti-inflammatory Drugs (NSAIDs), Corticosteroids), By Application (Autoimmune Inflammatory Diseases (Rheumatoid Arthritis Psoriasis), Respiratory Diseases), By Route of Administration (Oral, Injection, Inhalation, and Topical), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy), and Regional Forecast, 2020-2027Nebulizer Market Share & COVID-19 Impact Analysis, By Type (Jet Nebulizer, Ultrasonic Nebulizer, and Mesh Nebulizer) By Modality (Portable, and Table-top) By End User (Hospitals, Clinics, and Homecare Settings), and Regional Forecast, 2020-2027Cystic Fibrosis Market Share & Covid-19 Impact Analysis, By Drug Class (Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), Bronchodilators, Mucolytic, Pancreatic Enzyme Supplement, and Others), By Route of Administration (Oral, and Parenteral), By Distribution Channel (Retail Pharmacies & Drug Stores, Online Pharmacies, and Hospital Pharmacies), and Regional Forecast, 2020-2027 About Us:Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges. Contact Us:Fortune Business Insights™ Pvt. Ltd. 308, Supreme Headquarters, Survey No. 36, Baner, Pune-Bangalore Highway, Pune - 411045, Maharashtra, India.Phone: US :+1 424 253 0390 UK : +44 2071 939123 APAC : +91 744 740 1245 Email: firstname.lastname@example.org Fortune Business Insights™ LinkedIn | Twitter | Blogs Press Release: https://www.fortunebusinessinsights.com/press-release/telehealth-market-9211
Sidetrade (Euronext Growth: ALBFR.PA), the Artificial Intelligence platform dedicated to accelerating company revenue and cashflow, is pleased to announce a new partnership to bring AI to credit management and receivables. The Boss Cat, Order-to-Cash (O2C) transformation consultants, has signed a new partnership with Sidetrade, an artificial intelligence (AI) specialist, to solve business challenges around accounts receivable using their technology. Nigel Fields FCICM, senior consultant for The Boss Cat, said: “I’ve spent many years working with some major corporations with very complex global structures and various revenue streams. In my quest to seek out the best O2C solution that easily integrates with ERP & accounting systems, generally lacking in O2C functionality. I identified Sidetrade as the best O2C platform available today, with its AI assistant Aimie.”This partnership brings together the expertise of The Boss Cat and Sidetrade’s leading AI solutions, and will help companies to better manage their complex order-to-cash processes. “This intelligence ensures the best collection strategies for securing prompt payment along with the functionality for non-payment issues, risk management, dispute & deductions. It delivers faster cash & reduces risk. It also provides real-time reporting that is incredibly important to the CFO and senior board to make good strategic decisions.” \- Nigel Fields FCICM, The Boss CatThe customer experience will also get a revamp, by providing greater visibility and enhancing query management through configurable automations and workflows, which enable companies to improve revenue, productivity and customer satisfaction. Sidetrade feature’s an AI assistant, Aimie, in its O2C platform dedicated to accelerating company revenue and cashflow. “Sidetrade’s platform allows for teams to easily work remotely or from home ensuring that the workflow continues, and customers are properly serviced without disruption. It’s is a system fit for 2021 and beyond. Sidetrade continues to invest in their product for the benefit of all their clients and this is observed with their long-term relationships and increasing market share.” \- Nigel Fields FCICM, The Boss CatSunil Pandit, partner and alliance lead at Sidetrade said: “Digitalization and AI technology is transforming business. We all see the likes of Amazon, Microsoft, and Apple giving a great customer experience using automation and predictive analytics. We all want to better address our customer’s needs, improve their experience and maximize the cash for our own businesses. Our partnership with The Boss Cat will make a lasting impact for businesses who step ahead with AI for order-to-cash. Investor & Media relations - Sidetrade Christelle Dhrif +33 6 10 46 72 00 email@example.comAbout Sidetrade (www.sidetrade.com) Sidetrade (Euronext Growth: ALBFR.PA) accelerates growth by laying the cornerstones of the customer journey: acquisition, upsell/cross-sell, churn reduction, and payment. Integrated with your CRM and your ERP, Sidetrade’s revolutionary AI system called Aimie reveals unseen factors that can generate leads, drive new sales opportunities, improve retention and shorten payment delay. Over 1,500 businesses in 80 countries use Sidetrade technology to give their Marketing, Sales and Finance teams a competitive edge.For further information, visit us at www.sidetrade.com and follow us on Twitter @Sidetrade. Attachment * 201204_TheBossCat_PR
Britain hopes that millions of doses of the Pfizer/BioNTech COVID-19 vaccine will be delivered by the end of the year but the total will depend on how quickly it can be manufactured, Britain's business minister Alok Sharma said on Friday. Britain approved Pfizer Inc's COVID-19 vaccine on Wednesday, jumping ahead of the rest of the world in the race to begin the most crucial mass inoculation programme in history. Last month Britain said it expected 10 million doses of the shot in 2020, but the government has said the pace of roll-out will be dependence on delivery.
Brexit trade talks are in the difficult phase and a deal can only be struck if the European Union accepts that Britain is a sovereign nation, a British minister said on Friday after London indicated that the chance of a breakthrough was receding. With less than four weeks left until the United Kingdom finally exits the EU's orbit on Dec. 31, both sides are calling on the other to compromise over fishing, state aid and how to resolve any future disputes. As talks go down to the wire, a senior British government source said on Thursday that the prospect of a breakthrough was slipping but was still possible.
SYDNEY, AUSTRALIA / ACCESSWIRE / December 4, 2020 / Business coach Rashid Mubashir overcame poverty to reach his goals and is now turning over a six-figure business devoting himself to empowering others to achieve theirs.
Hungary still cannot accept a clause on respecting the rule of law attached to the European Union's budget and coronavirus recovery fund, Prime Minister Viktor Orban said on Friday, adding that the issues should be dealt with separately. Hungary and Poland have blocked the EU's seven-year budget and its post-crisis development fund for weeks, holding up 1.85 trillion euros ($2.25 trillion) worth of funds from reaching member states, some hurting for cash amid an economic crisis. "For us this solution, attaching some statement like a reminder on a sticky note attached on a piece of paper, it won't work," Orban told public radio.
Paris, December 4, 2020, 8.30amAB Science announces that confirmatory Phase 3 study AB12005 with masitinib in first line pancreatic cancer with pain was successful and reached its primary objective to show statistically significant increase in survivalAB Science SA (Euronext - FR0010557264 - AB) today announced that its Phase 3 study (AB12005 - NCT03766295) met its primary objective to demonstrate increase in survival in pancreatic cancer with pain.Study AB12005 evaluated masitinib 6.0 mg/kg/day in combination with gemcitabine in first-line treatment of unresectable locally advanced or metastatic pancreatic cancer patients with pain. The study was successful if its primary objective to test a significant increase in overall survival was reached at a 2.5% level of statistical significance in either the overall population with pain or in the population with unresectable locally advanced tumors with pain.In the population with unresectable locally advanced tumors with pain, the masitinib treatment-arm showed a significant improvement in overall survival (OS) relative to the control arm. The between group difference in median OS was 1.8 months (p=0.007) in favor of masitinib (13.0 months in masitinib arm versus 11.2 months in control group), with a 0.46 hazard ratio (HR) of death, which represents a reduction in risk of death of 54% for masitinib-treated patients relative to control. Results on the primary endpoint were consistent with secondary analysis in progression free survival (PFS), which measures the time to tumor progression or death (whichever occurs first) from the start of treatment. The between group difference in median PFS was 1.8 months (p=0.039) in favor of masitinib (7.4 months in masitinib arm versus 5.6 months in control group), with a 0.47 hazard ratio representing a reduction in risk of having a progression or death of 53%.Masitinib also reduced pain relative to the control arm in patients with unresectable locally advanced tumors, as demonstrated by a between group difference that reached statistical significance or approached significance at each timepoint. In pancreatic cancer, there is evidence that pain is a clinical predictor of poor prognosis . Study AB12005 demonstrated that mast cells are associated with pain and that blocking mast cells, as masitinib does, is able to reverse the poor prognosis of patients with unresectable locally advanced tumors with pain.In the overall population including both locally advanced and metastatic pancreatic cancer patients with pain, no survival benefit was detected, suggesting that masitinib treatment should be initiated early in the course of the disease, prior to metastasis.From the first Phase 3 study AB07012  and literature , around 50% of patients with pancreatic cancer had pain intensity (VAS > 20) and 25% to 50% of pancreatic cancer patients are patients with unresectable locally advanced tumors.The safety of masitinib 6.0 mg/kg/day in combination with gemcitabine compared favorably to that of gemcitabine as a single agent, with fewer adverse event and severe adverse events reported in the masitinib arm as compared with the control arm: * 96.3% of patients had at least one adverse event in masitinib arm versus 99.3% in the control arm * 18.7% of patients had one fatal adverse event in masitinib arm versus 19.1% in the control arm * 19.1% of patients had at least one serious adverse event (non-fatal) in masitinib arm versus 21.3% in the control arm * 74.8% of patients had at least one adverse event with Grade 3 or 4 in masitinib arm versus 83.1% in the control armStudy AB12005 was a confirmatory Phase 3 study. The first Phase 3 study (AB07012) was a hypothesis generating study and identified that patients with pain had a median OS increased by 2.6 months (p=0.012) with masitinib as compared to control. Study AB12005 demonstrated that there is a benefit generated by masitinib for pancreatic cancer patients with pain, provided that treatment is initiated prior to metastasis.Dr. Joël Ezenfis, MD, principal coordinating investigator of the study, said: “We are very pleased that this study is successful. The increase of 1.8 months in median overall survival for masitinib-treated patients is clinically relevant as this population of patients suffers from a condition with very limited treatment options and survival rate has remained stubbornly poor despite decades of clinical studies.”Julien Taieb, MD, PhD, Head of the Gastroenterology and Gastrointestinal Oncology Department at the Georges Pompidou European Hospital said: “Masitinib is not a cytotoxic agent but a targeted drug blocking two cells of the innate immune system, mast cells and macrophages. Study AB12005 demonstrated for the first time that this targeted approach is beneficial in a targeted population, made of patients with unresectable locally advanced tumors with pain”.Prof. Olivier Hermine, president of the Scientific Committee of AB Science and member of the Académie des Sciences in France, said: “This study is particularly important as it confirms the relevance of targeting mast cells and macrophages in oncology. We had previously observed the benefit of masitinib targeting mast cells and macrophages in cancer through in vitro and in animal assays in my laboratory. This study validates the benefit of masitinib in humans in the most difficult-to-treat cancer. We can now state that masitinib is an anti-metastatic drug that could be useful in patients at high risk of developing metastases. In addition, it validates the role of mast cells in pain and the acceptable safety profile of masitinib even in combination with chemotherapy.”Alain Moussy, co-founder and CEO of AB Science said: “This is a major achievement for masitinib in oncology. The next step is to discuss with the Health Authorities a potential filing for marketing authorization application of masitinib in the first line treatment of unresectable locally advanced pancreatic cancer associated with pain”. AB Science plans to present complete study results at an upcoming medical meeting.AB12005 Study DesignStudy AB12005 was a randomized, placebo-controlled, phase 3 study of masitinib in first-line treatment of unresectable locally advanced or metastatic pancreatic cancer patients with pain at baseline or taking opioids.The pre-specified primary endpoint was overall survival. The primary analysis was pre-specified both in the overall population and also in patients with unresectable locally advanced tumors, with a 5% alpha spending split, which corresponds to the chance factor threshold below which the statistical test is considered significant by regulatory authorities, of 2.5% for the overall population and 2.5% for the locally advanced subgroup. The distinction between unresectable locally advanced or metastatic disease status was a stratification factor, thereby ensuring that treatment-arms were unbiased for this known prognostic factor. Secondary endpoints included progression free survival according to central RECIST criteria and change in pain from baseline.The study enrolled 383 patients (randomization 2:1 between masitinib and placebo) with i) histologically or cytologically confirmed adenocarcinoma of the pancreas, unresectable locally advanced or metastatic stage, ii) pain related to the disease (Visual Analogue Scale > 20 mm or opioid analgesics at a dose ≥ 1 mg/kg/day), and iii) chemotherapy naïve for the advanced/metastatic disease. 92 patients had unresectable locally advanced with pain criteria.Efficacy analysis was performed in the modified intent-to-treat (mITT) population, which included all randomized patients who took at least one dose of study treatment (masitinib/placebo) and with pain criteria (VAS > 20 and/or patients treated with opioid analgesics dose ≥ 1 mg/kg/day at baseline). There was a difference of 4 patients between the ITT population and the mITT population, with 1 patient receiving no study treatment and 3 patients without pain criteria.Rationale for developing masitinib in patients with pancreatic cancer with painA first phase 2/3 study (AB07012) enabled the identification of a subgroup based on the level of pain at baseline where survival was statistically increased (+2.6 months, p=0.012, Hazard Ratio=0.62). Pain intensity was assessed via a visual analog scale (VAS) at baseline. This linear scale provides a visual representation of pain as perceived by the patient. Pain intensity was represented by a 100 mm long, continuous line free of any internal reference marks. One extremity indicated an absence of pain (0-value) and the other extremity indicated very severe pain (100-value). The VAS threshold for the ‘pain’ subgroup was set to VAS ≥20 mm, which is consistent with established precedent from the scientific literature [3-6]. There is evidence from the scientific literature in support of biological plausibility for the observed masitinib treatment-effect in patients with baseline pain (VAS ≥ 20). The presence of pain in pancreatic cancer is thought to flag an increased mast cell activity within the tumor microenvironment, which promotes disease progression. Masitinib’s highly selective inhibition of mast cell activation is expected to be of therapeutic benefit by modulating mast cell related remodeling of the tumor microenvironment. About pancreatic cancer The estimated prevalence of people living with pancreatic cancer is 21 per 100,000 . At the time of diagnosis, most patients with pancreatic ductal adenocarcinoma present with locally advanced or metastatic disease and only 10-20% of cases are candidates for curative surgery. Median overall survival is between 6 to 7 months and 1-year survival rates range between 17 to 25% [8;9]. As such, population with unresectable pancreatic cancer in first line is around 100,000 in the EU and 60,000 in the USA. From the first Phase 3 study AB07012  and literature , around 50% of patients with pancreatic cancer had pain intensity (VAS > 20) and 25% to 50% of pancreatic cancer patients are patients with unresectable locally advanced tumors.Reference Okusaka T, et al. Abdominal pain in patients with resectable pancreatic cancer with reference to clinicopathologic findings. Pancreas. 2001;22(3):279-284.  Deplanque 2015, Ann Oncol. doi: 10.1093/annonc/mdv133. http://annonc.oxfordjournals.org/content/26/6/1194 Balaban EP, et al. Locally Advanced Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary. J Oncol Pract. 2017 Apr;13(4):265-269. doi: 10.1200/JOP.2016.017376.  Khazaie K, Blatner NR, Khan MW, et al. The significant role of mast cells in cancer. Cancer Metastasis Rev. Mar 2011;30(1):45-60.  Theoharides TC. Mast cells and pancreatic cancer. N Engl J Med. Apr 24 2008;358(17):1860-1861.  Maltby S, Khazaie K, McNagny KM. Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation. Biochim Biophys Acta. Aug 2009;1796(1):19-26.  Christy AL, Brown MA. The multitasking mast cell: positive and negative roles in the progression of autoimmunity. J Immunol. Sep 1 2007;179(5):2673-2679 National Cancer Institute, Pancreatic Cancer statistics, 2015  Heinemann V, et al. BMC Cancer. 2008;8:82.  Von Hoff DD, et al. N Engl J Med. Oct 31 2013;369(18):1691-1703.About masitinib Masitinib is a new orally administered tyrosine kinase inhibitor that targets mast cells and macrophages, important cells for immunity, through inhibiting a limited number of kinases. Based on its unique mechanism of action, masitinib can be developed in a large number of conditions in oncology, in inflammatory diseases, and in certain diseases of the central nervous system. In oncology due to its immunotherapy effect, masitinib can have an effect on survival, alone or in combination with chemotherapy. Through its activity on mast cells and microglia and consequently the inhibition of the activation of the inflammatory process, masitinib can have an effect on the symptoms associated with some inflammatory and central nervous system diseases and the degeneration of these diseases.About AB Science Founded in 2001, AB Science is a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), a class of targeted proteins whose action are key in signaling pathways within cells. Our programs target only diseases with high unmet medical needs, often lethal with short term survival or rare or refractory to previous line of treatment. AB Science has developed a proprietary portfolio of molecules and the Company’s lead compound, masitinib, has already been registered for veterinary medicine and is developed in human medicine in oncology, neurological diseases, and inflammatory diseases. The company is headquartered in Paris, France, and listed on Euronext Paris (ticker: AB).Further information is available on AB Science’s website: www.ab-science.com.Forward-looking Statements - AB Science This press release contains forward-looking statements. These statements are not historical facts. These statements include projections and estimates as well as the assumptions on which they are based, statements based on projects, objectives, intentions and expectations regarding financial results, events, operations, future services, product development and their potential or future performance.These forward-looking statements can often be identified by the words "expect", "anticipate", "believe", "intend", "estimate" or "plan" as well as other similar terms. While AB Science believes these forward-looking statements are reasonable, investors are cautioned that these forward-looking statements are subject to numerous risks and uncertainties that are difficult to predict and generally beyond the control of AB Science and which may imply that results and actual events significantly differ from those expressed, induced or anticipated in the forward-looking information and statements. These risks and uncertainties include the uncertainties related to product development of the Company which may not be successful or to the marketing authorizations granted by competent authorities or, more generally, any factors that may affect marketing capacity of the products developed by AB Science, as well as those developed or identified in the public documents filed by AB Science with the Autorité des Marchés Financiers (AMF), including those listed in the Chapter 4 "Risk Factors" of AB Science reference document filed with the AMF on November 22, 2016, under the number R. 16-078. AB Science disclaims any obligation or undertaking to update the forward-looking information and statements, subject to the applicable regulations, in particular articles 223-1 et seq. of the AMF General Regulations.For additional information, please contact:AB Science Financial Communication firstname.lastname@example.orgRooneyPartners Media Relations – USA Jeffrey Freedman email@example.com+1 646 432 0191NewCap Media Relations – France Arthur Rouillé firstname.lastname@example.org+33 (0)1 44 71 00 15Attachment * CP Pancreatic Final VEng VF
The Seoul Tourism Organization (STO) (President Jae-sung Rhee) announced that its new designs of the Discover Seoul Pass with expanded services will improve the convenience of individual tourists.
“This metastasizing debt crisis has had tremendous social costs. An entire generation has been set back.”
“It is not the government’s job to step in and rescue those who took on more debt than their future incomes would support.”
“Many student-borrowers need relief, but well-off borrowers who are thriving — thanks to their college degrees — do not.”
“It will stimulate the lagging economy. And though not everyone will directly benefit, the country as a whole will improve.”
“Canceling student debt would cost billions of dollars each year and would exacerbate, not lessen, economic inequalities.”